Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Buagafuran PK and Safety in Hepatic Impairment
NCT07457190Phase 1Not yet recruiting
- Sponsor
- Beijing Union Pharmaceutical Factory
- Start
- Mar 2026
- Primary completion
- Aug 2026
- Countries
- 1
01
Overview
Phase 1, open-label trial of buagafuran in generalized anxiety disorder (GAD) (3 arms), sponsored by Beijing Union Pharmaceutical Factory. Primary endpoints: Maximum Plasma Concentration, Area Under the Curve from time zero to the last quantifiable concentration and 1 more. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
buagafuran
03
Conditions
generalized anxiety disorder (GAD)
Beyond the preview
Go deeper on NCT07457190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07457190.